stockrowCibus, Inc.
CBUS Healthcare Biotechnology
Cibus, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.6 million, down 14.6% from fiscal 2024.
- Revenue
- +6.54%
- EPS
- +52.5%
- Free cash flow
- +31.6%
- Total debt
- −62.1%
Quarter to June 2026, against a year earlier
Follow CBUS
Alert me
Cibus, Inc. (CBUS) EV/Sales
As of 6 November 2026, Cibus, Inc. (CBUS) trades at a EV/Sales of 16.2×. Over the past ten years it has ranged from −0.4× (September 2022) to 2,145× (March 2019); the current reading is higher than 42% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 19.5× | 0.40% |
| FY2024 | 19.4× | (77.77%) |
| FY2023 | 87.1× | (17.10%) |
| FY2022 | 105× | 3,176.23% |
| FY2021 | 3.2× | (42.61%) |
| FY2020 | 5.6× | (78.48%) |
| FY2019 | 26.0× | (97.47%) |
| FY2018 | 1,025× | 4.90% |
| FY2017 | 977× | 6,250.89% |
| FY2016 | 15.4× | 0.00% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 19.7× | (15.30%) |
| Mar 2026 | 23.3× | 19.76% |
| Dec 2025 | 19.5× | 62.19% |
| Sep 2025 | 12.0× | 162.86% |
| 38 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SEER Seer, Inc. compare | −4.4× |
| MIST Milestone Pharmaceuticals Inc. compare | −1.1× |
| RLYB Rallybio Corporation compare | −0.8× |
| PLYX Polaryx Therapeutics, Inc. compare | n/m |
| EQ Equillium, Inc. compare | 2.9× |
| ICCC ImmuCell Corporation compare | 2.9× |
| VTVT vTv Therapeutics Inc. compare | 4.7× |
| CBUS Cibus, Inc. | 16.2× |
| RTSN Retension Pharmaceuticals, Inc. compare | — |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)